Both studies by Sineshaw et al. and Garg et al. identified the dominance of R-CHOP as 1L therapy (Sineshaw et al. study, 63.6%; Garg et al study, 61.2%) for DLBCL, the lack of established standard regimens in later LOT, and the worsening survival outcomes with later LOT. Here, DDIT3 is linked to diffuse large B-cell lymphoma.